Hypereosinophilic Syndrome (HES) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Hypereosinophilic Syndrome (HES) Market Outlook

Thelansis’s “Hypereosinophilic Syndrome (HES) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hypereosinophilic Syndrome (HES) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Hypereosinophilic Syndrome (HES) Overview

Hypereosinophilic Syndrome (HES) is a group of disorders characterized by elevated blood eosinophil counts (>1.5 × 109/L) and resultant organ damage, commonly affecting the heart. Initially, the term referred to the combination of peripheral blood eosinophilia and tissue infiltrates leading to dysfunction or damage. The “idiopathic” label reflected the lack of knowledge regarding underlying causes, excluding known diseases such as drug allergies, parasitic infections, cancer, lymphoma and myeloproliferative disorders. Symptoms of HES can vary greatly among patients and include skin rashes, dizziness, memory loss, coughing, shortness of breath, fatigue, fever, and mouth sores. Organ damage or dysfunction occurs due to the release of cytotoxic substances by eosinophils, including eosinophil cationic protein, major basic protein, ribonuclease eosinophil derived neurotoxin, eosinophil peroxidase, and enzymes such as elastase and collagenase. Eosinophils also secrete cytokines and chemokines, contributing to the immune response, and can lead to fibrotic changes due to increased collagen synthesis. Current diagnostic criteria for HES suggest that two distinct mechanisms may underlie chronic, unexplained hypereosinophilia in HES patients. One mechanism involves a sporadic hematopoietic stem cell mutation resulting in clonal expansion of eosinophilic cells, and the other involves an overproduction of eosinophilopoietic cytokines by activated T cells. Classifying HES patients can be challenging and requires specialized laboratory evaluation. Predominant skin symptoms without heart involvement, along with serum hyper IgE or polyclonal hypergammaglobulinemia, may suggest the lymphocytic variant of HES. Treatment options for HES include high-dose oral corticosteroids, interferon alpha, hydroxyurea, and PUVA therapy. Approximately 70% of patients respond to oral prednisone therapy with normalization of eosinophil counts. The 5-year survival rate for HES patients is 80%, with heart failure being the most common cause of death.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Hypereosinophilic Syndrome (HES) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034